The CooperCOO +4.04%85 EBITDA Margin % is 6.28% as of Apr. 2026, which is 77% below its 10-year median of 26.90. GuruFocus rates COO with a GF Score™ of 85/100 and a GF Value™ of $100.85 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 816 Medical Devices & Instruments companies, The Cooper ranks better than 77.33% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. The Cooper's EBITDA for the
three
months ended in Apr. 2026 was $68 Mil. The Cooper's Revenue for the
three
months ended in Apr. 2026 was $1,082 Mil. Therefore, The Cooper's EBITDA margin for the quarter that ended in Apr. 2026 was 6.28%.
The Cooper (NAS:COO) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
The Cooper EBITDA Margin % Related Terms
The Cooper EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for The Cooper's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COO vs ALGN, SOLV, BAX: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, The Cooper's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where The Cooper's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Cooper (COO) has a EBITDA Margin % of 6.28% as of Apr. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on The Cooper and its competitors. This is 77% below median its historical median of 26.90. Over the past decade, The Cooper's EBITDA Margin % has ranged from 21.04 to 31.14. According to the industry distribution chart, The Cooper ranks #185 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 22.7%.
Is The Cooper's EBITDA Margin % too high?
The Cooper's current EBITDA Margin % of 6.28% is 77% below median its 10-year median of 26.90. Over the past 10 years, this metric has ranged from a low of 21.04 to a high of 31.14. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. The Cooper's value of 6.28% is 16% below this industry median. Based on the distribution chart, The Cooper ranks #185 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, The Cooper has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's EBITDA Margin % compare to ALGN and SOLV?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #185 out of 816 companies for EBITDA Margin %. This places The Cooper in the top 23% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. The Cooper's value of 6.28% is 16% below this benchmark. Historically, The Cooper's own EBITDA Margin % has ranged from 21.04 to 31.14 over the past decade. While the company's 10-year median is 26.90 vs. the industry median of 7.48, The Cooper has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cooper's current EBITDA Margin % of 6.28% is 16% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current EBITDA Margin % is 6.28%, which is 77% below median its own 10-year median of 26.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Significantly Undervalued. The stock's GF Value™ is $100.85, compared to a current price of $68.86 — trading 31.7% below its estimated fair value. The current EBITDA Margin % is 6.28%, which is 77% below median its 10-year median of 26.90 and 16% below the Medical Devices & Instruments industry median of 7.48. The Cooper's overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For The Cooper (COO), the current EBITDA Margin % is 6.28% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $68.86 is trading 31.7% below its estimated GF Value™ of $100.85.
GuruFocus considers The Cooper to be Significantly Undervalued.
Key valuation signals for COO:
EBITDA Margin %: 6.28% (77% below median its 10-year median of 26.90)
GF Value™: $100.85 vs. price of $68.86 (31.7% below fair value)
Industry Position: 16% below the Medical Devices & Instruments median (#185 of 816)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
85GF Score
Get the complete analysis for COO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
